Pharmaceutical Engineering Magazine

Plastic Process Waste in Biopharmaceutical Manufacturing Cover: This article presents a comprehensive analysis of plastic waste generation in the...

PIC/S in Latin America: Harmonization of cGMP Procedures Cover: This article offers an overview of the benefits of Pharmaceutical Inspection Co...

The explosive growth of advanced therapy medicinal products (ATMPs), particularly cellular therapeutics, has driven steady investment in facilities capable of manufacturing these therapeutics at scale. Meanwhile, the industry is collectively moving to adapt to European Union Annex 1 standards, which places a more stringent emphasis on contamination control.

The commercialization of personalized medicine has ushered in demand for a new type of facility— personalized medicine facilities—which can produce thousands of small-scale batches per year. There are currently only a handful of these sites, but many more are in various stages of design and construction. Designing these personalized medicine facilities presents new challenges, and a different design approach is necessary. Cyclic scheduling can produce high-quality models rapidly and aid collaborative design. A focus on room and zone availability and movements can prevent bottlenecks in corridors, gowning, and airlocks to streamline production.

Navigating the Asia Pacific Pharmaceutical Landscape for Global Impact Cover: The Asia Pacific region (APAC), like any large territory, encompasses a...

Stakeholders across industries are becoming accustomed to using information technology (IT) systems, applications, and business solutions that feature artificial intelligence (AI) and machine learning (ML). Even though some of these uses show phenomenal performance, thorough risk management is required to ensure quality and regulatory compliance are met within the life sciences industry. By leveraging specialized frameworks and methods, we compiled a holistic framework to dynamically identify, assess, and mitigate risks when AI and ML features are in use.

There is much that large-scale commercial stem cell therapy processes can adopt from the existing bioprocessing industry. This article addresses some of the unique challenges posed by large-scale stem cell and stem cell–derived product manufacturing processes, and what should be considered while designing a manufacturing facility.

Regulatory Trends & Quality Initiatives - Shortages of essential medicines around the world have been an ongoing concern for patients, caregivers, and regulators and have been exacerbated by the COVID-19 pandemic. Many regulators have instituted requirements for reporting potential or actual drug shortages. To further minimize drug shortages, regulators in the United States and France recently established requirements for risk management on drug shortages avoidance. Such requirements could spread beyond these two countries, especially because risk management for product availability is included in the revision of the ICH Q9(R1) guideline “Quality Risk Management.” Shortages of essential medicines around the world have been an ongoing concern for patients, caregivers, and regulators and have been exacerbated by the COVID-19 pandemic. Many regulators have instituted requirements for reporting potential or actual drug shortages. To further minimize drug shortages, regulators in the United States and France recently established requirements for risk management on drug shortages avoidance. Such requirements could spread beyond these two countries, especially because risk management for product availability is included in the revision of the ICH Q9(R1) guideline “Quality Risk Management.”

Continuous manufacturing (CM) challenged regulators’ expectations and regulatory frameworks. This article discusses how US regulators addressed the regulatory hurdles related to CM to broaden its adoption through engagement, regulatory science, guidance, and international harmonization.

North Carolina’s Research Triangle is the largest of its kind in the US. Thanks to years of effort from industry, pharmaceutical professionals, and education institutions, it is synonymous with pharmaceutical and biotechnology excellence.